Glenn Schulman
Investor Relations Kontakt bei IN8BIO, INC.
Profil
Glenn Schulman is currently the VP, Head-Investor Relations & Communications at IN8bio, Inc. He previously worked as the Director-Investor Relations at CuraGen Corp., Investor Relations Contact at Achillion Pharmaceuticals, Inc., Senior VP-Communications & Investor Relations at Aurinia Pharmaceuticals, Inc., VP-Investor Relations & Corporate Communications at X4 Pharmaceuticals, Inc., and Senior Vice President-Investor Relations at ProKidney Corp.
Dr. Schulman holds a graduate degree from Yale University, an undergraduate degree from Philadelphia College of Pharmacy, and a doctorate degree from Ernest Mario School of Pharmacy.
Aktive Positionen von Glenn Schulman
| Unternehmen | Position | Beginn |
|---|---|---|
| IN8BIO, INC. | Investor Relations Kontakt | 01.04.2024 |
Ehemalige bekannte Positionen von Glenn Schulman
| Unternehmen | Position | Ende |
|---|---|---|
| PROKIDNEY CORP. | Investor Relations Kontakt | - |
| X4 PHARMACEUTICALS, INC. | Investor Relations Kontakt | - |
| ACHILLION PHARMACEUTICALS, INC. | Public Communications Contact | - |
| AURINIA PHARMACEUTICALS INC. | Investor Relations Kontakt | 15.07.2022 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Public Communications Contact | - |
Ausbildung von Glenn Schulman
| Philadelphia College of Pharmacy | Undergraduate Degree |
| Ernest Mario School of Pharmacy | Doctorate Degree |
| Yale University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| AURINIA PHARMACEUTICALS INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| PROKIDNEY CORP. | Health Technology |
| IN8BIO, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
